O nível sérico de NT-proBNP é um preditor prognóstico em pacientes com insuficiência cardíaca avançada

Abstract

M a i l i n g A d d r e s s : A n t o n i o C a r l o s P e r e i r a B a r r e t t o• R u a P i a v e , 1 0 3 -0 5 6 2 0 -0 1 0 -S ã o P a u l o , S P -B r a z i l E-mail: pereira.barretto@incor.usp. OBJECTIVETo verify if the determination of NT-proBNP values would help predict the prognosis in advanced heart failure (HF) patients. METHODSOne hundred and five subjects with average age of 52.4 years were evaluated, 66.6% of them males. Thirty-three (32.0%) subjects were outpatients and 70 (67.9%) were inpatients (functional class III/IV) admitted to the hospital for cardiac compensation. All patients had left ventricular systolic dysfunction and a mean ejection fraction of 0.29. The NT-proBNP levels were measured in all patients and they were followed-up over a period ranging from 2 to 90 days (average 77 days). A ROC curve was drawn to determine the best cut-off point, as well as the corresponding Kaplan-Meyer survival curves.

Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID)

“…To evaluate potential biological response at an individual level, results of large HF clinical trials were reviewed and expert opinions were collected. Thresholds of clinically meaningful changes were established based on the magnitude of changes associated with improvement or worsening in clinical outcomes (including mortality/morbidity) and parameter variability as follows: a 1-class change in NYHA classification, 25 a 10-point change in total MLWHFQ score, 26-29 a 50-meter change in the 6MWT, 25-30 a 1.5-mL kg min change in VO 2 max,25 a change in NT-proBNP of 35% or 300 pg/mL, whichever is greater, 31-34 a change in LVESV of 20 mL or 10%, whichever is greater, and a change in LVEF of at least 5% (absolute). 35 …”